Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-08-21Clinical Trial Update: Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
Non-interventional (observational) study in patients with advanced or metastatic renal cell carcinoma treated with SUTENT (sorafenib) comple…
-
CLINICAL_TRIALS trial_result · 2012-08-03Clinical Trial Update: TachoComb S Versus Standard Surgical Treatment in Surgical Resection of Renal Tumour (TC-015-IN) [Phase 3]
Phase 3 trial TC-015-IN compares TachoComb S to standard surgical treatment for surgical resection of superficial renal tumours; the study s…
-
CLINICAL_TRIALS withdrawal · 2012-07-31Clinical Trial Update: Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma [Phase 2]
A Phase 2 study of sunitinib in patients with high-risk renal cell carcinoma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2012-07-20Clinical Trial Update: BMS 247550 to Treat Kidney Cancer [Phase 2]
Phase 2 trial of BMS 247550 for renal cell carcinoma has completed and results were posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-07-12Clinical Trial Update: Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery [Phase 2]
A Phase 2 trial evaluated celecoxib in combination with recombinant interferon alfa-2b in metastatic renal cell carcinoma after surgery; the…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2012-07-11Clinical Trial Update: Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer [Phase 3]
Phase 3 trial comparing interferon alfa with and without isotretinoin for metastatic renal cell carcinoma completed.
-
CLINICAL_TRIALS trial_result · 2012-07-10Clinical Trial Update: IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease [Phase 2]
Phase 2 trial update showing that the IMA901 study in advanced renal cell carcinoma with measurable disease has completed.
-
CLINICAL_TRIALS trial_result · 2012-07-09Clinical Trial Update: Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma [Phase 2]
Phase 2 study evaluating temsirolimus in advanced renal cell carcinoma has completed with results on safety, efficacy, and pharmacokinetics …
-
CLINICAL_TRIALS trial_result · 2012-06-15Clinical Trial Update: A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®
A completed clinical trial evaluated the characteristics of patients with advanced renal cell carcinoma treated with Nexavar (sorafenib).
-
CLINICAL_TRIALS trial_result · 2012-06-14Clinical Trial Update: Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma [Phase 2]
Phase 2 trial of a vaccine therapy using tumor-specific mutated VHL peptides in adults with renal cell carcinoma was terminated; results wer…
-
CLINICAL_TRIALS trial_result · 2012-06-14Clinical Trial Update: Hepatic and Renal Thermography Using Magnetic Resonance Imaging [NA]
A clinical trial evaluating hepatic and renal thermography using magnetic resonance imaging conducted by University Hospital, Bordeaux has b…
-
CLINICAL_TRIALS trial_result · 2012-06-06Clinical Trial Update: Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma [Phase 1]
A Phase 1 dose-finding study of CP-675,206 and SU011248 in metastatic renal cell carcinoma has completed. The trial evaluated safety and ide…
-
FDA approval · 2012-05-30FDA Approved: TORISEL — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for Torisel (temsirolimus) filed by Wyeth Pharmaceuticals (Pfizer).
-
CLINICAL_TRIALS trial_result · 2012-05-16Clinical Trial Update: Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma [Phase 3]
A Phase 3 trial evaluating capecitabine in combination with immunotherapy versus immunotherapy alone in advanced renal cell carcinoma was te…
-
CLINICAL_TRIALS trial_result · 2012-05-03Clinical Trial Update: Pemetrexed Plus Gemcitabine in Renal Cell Cancer [Phase 2]
Phase 2 trial evaluating pemetrexed plus gemcitabine in renal cell carcinoma was terminated; results were posted in 2012.
-
FDA approval · 2012-04-26FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2012-04-19Clinical Trial Update: Cost Effectiveness Of Sunitinib In Central America And Caribbean
Pfizer-sponsored trial evaluating the cost-effectiveness of sunitinib for metastatic renal cell carcinoma in Central America and the Caribbe…
-
CLINICAL_TRIALS trial_result · 2012-04-17Clinical Trial Update: EPO906 Therapy in Patients With Advanced Kidney Cancer [Phase 2]
A Phase 2 trial of EPO906 Therapy in patients with advanced kidney cancer has completed, with an update from Novartis on the study status.
-
CLINICAL_TRIALS research · 2012-04-11Clinical Trial Update: Temsirolimus-RCC-imaging [Phase 2]
Phase 2 clinical trial update on temsirolimus for renal cell carcinoma with an imaging focus; current trial status is unknown.
-
CLINICAL_TRIALS trial_result · 2012-04-03Clinical Trial Update: Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer [Phase 2]
A Phase 2 trial of AG-013736 (axitinib) in patients with refractory metastatic renal cell carcinoma has completed, with results posted in 20…
-
CLINICAL_TRIALS trial_result · 2012-03-28Clinical Trial Update: Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
Pfizer conducted a retrospective observational update to report 5-year survival of subjects who participated in Axitinib trial A4061012; res…
-
CLINICAL_TRIALS trial_result · 2012-03-27Clinical Trial Update: Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer [Phase 3]
Phase 3 trial update on axitinib as second-line therapy for metastatic renal cell cancer completed with results posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-03-27Clinical Trial Update: Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC) [Phase 2]
Phase 2 trial update of axitinib as second-line treatment for metastatic renal cell carcinoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2012-03-19Clinical Trial Update: Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma [Phase 2]
Phase 2 study of AG-013736 (cediranib) in patients with metastatic renal cell carcinoma completed; results were posted in 2012.
-
CLINICAL_TRIALS trial_result · 2012-03-15Clinical Trial Update: Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer [Phase 2]
This document reports the results of a Phase 2 clinical trial of a monoclonal antibody therapy in patients with metastatic renal cell carcin…